Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder
Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder
复制标题
DOI：
10.1111/bju.13025
复制
发表时间：
2015-09-01
影响因子：
4.5
通讯作者：
Sahai, Arun
中科院分区：
文献类型：
--
作者：
Malde, Sachin;Dowson, Christopher;Sahai, Arun
目的评估我们的专用肉毒杆菌毒素A（BTX-A）的服务，使用一个有效的患者报告的经验措施（PREM）和评估患者报告的治疗满意度与treatment.Materials和MethodsThe第一个100例接受BTX-A治疗难治性特发性逼尿肌过度活动症（IDO）在我们的机构进行了电话采访。他们都在一家专门的BTX-A诊所接受了评估、注射和随访。患者被要求完成一个有效的PREM -客户满意度问卷（CSQ-8）-以及在我们部门开发的问卷，以评估对治疗结果的满意度。大多数患者接受200 U OnabotulinumtoxinA（肉毒杆菌（R））通过门诊局部麻醉的灵活cystoscopy technique.ResultsComplete data为72例。总共有49名患者继续接受BTX-A治疗，而23名患者选择不再注射。总体平均（SD）CSQ-8满意度评分为38.3（3.3），表明患者对我们机构提供的服务满意度较高。A型肉毒毒素治疗组与停药组的满意度比较，差异有统计学意义（P < 0.01）。患者对治疗结果的总体满意度较高，视觉模拟量表的总体平均（SD）评分为8.6（2.0）。那些谁已经停止BTX-A，大多数要么使用保守的措施只（44%）或重新开始抗胆碱能药物。ConclusionOverall patient satisfaction with the dedicated BTX-A service provided in our institution is high and can result in a positive patient experience.提倡使用PREM，以充分了解患者对他们所接受的服务和治疗质量的看法。
ObjectiveTo evaluate the patient experience of our dedicated botulinum toxin A (BTX-A) service using a validated patient-reported experience measure (PREM) and assess patient-reported satisfaction with treatment.Materials and MethodsThe first 100 patients who underwent BTX-A treatment for refractory idiopathic detrusor overactivity (IDO) in our institution were contacted for telephone interview. They had all been assessed, injected and followed up in a dedicated BTX-A clinic. Patients were asked to complete a validated PREM - the Client Satisfaction Questionnaire (CSQ-8) - as well as a questionnaire developed in our department to assess satisfaction with the results of the treatment. Most patients received 200 U OnabotulinumtoxinA (Botox (R)) via an outpatient local anaesthetic flexible cystoscopy technique.ResultsComplete data was available for 72 patients. In all, 49 patients were continuing to receive BTX-A treatment while 23 had opted for no further injections. The overall mean (SD) CSQ-8 satisfaction score was 38.3 (3.3), indicating a high level of patient satisfaction with the service offered in our institution. There was a significant difference in total satisfaction scores between those still receiving BTX-A (mean score 29.8) and those who have discontinued treatment (mean score 25.1) (P < 0.01). Overall patient satisfaction with the result of the treatment was high with an overall mean (SD) score of 8.6 (2.0) on a visual analogue scale. Of those who had discontinued BTX-A, most were either using conservative measures only (44%) or had recommenced anticholinergic medications.ConclusionOverall patient satisfaction with the dedicated BTX-A service offered in our institution is high and can result in a positive patient experience. The use of PREMs are advocated in order to fully capture the patient's views of the quality of services and treatments they receive.